Myungin Pharm
명인제약 · 317450
Health Care Pharmaceuticals · KOSPI
Market cap US$480.8M (₩663.6B)
Overview
Myungin Pharm makes prescription medicines that act on the central nervous system, drugs used to treat conditions such as stroke, Parkinson's disease, schizophrenia, and depression, as well as over-the-counter products including a gum-health supplement and a constipation remedy.
Its medicines are prescribed by doctors in South Korea and the company also supplies global pharmaceutical partners in markets including the United States, Europe, China, and Japan. Listed on KOSPI, South Korea's main stock exchange, the company derives nearly all of its revenue from pharmaceutical sales, with prescription drugs making up the large majority of that.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2025US$208.2M
Operating profit
- FY2025US$67M
Net income
- FY2025US$59M
Key ratios (FY2025)
Why it matters
The company covers the full production chain, from active-ingredient synthesis through to finished-dose manufacturing, built to the standards required by current Good Manufacturing Practice (cGMP) guidelines.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?